Showing 5011-5020 of 6808 results for "".
- Long-term Outcomes Impaired by Cutaneous Chronic Graft-vs-Host Diseasehttps://practicaldermatology.com/news/improved-melanoma-prognosis-with-31-gep/2462255/New analysis results indicate that cutaneous chronic graft-vs-host disease (GVHD) was linked with impaired long-term patient-reported outcomes (PROs). Researchers for the 9-center study conducted by the Chronic GVHD Consortium examined the association between different ty
- Study: Test Improves the Risk Stratification of Patients with Stage I Melanomahttps://practicaldermatology.com/news/study-finds-decisiondx-melanoma-significantly-improves-the-risk-stratification-of-patients-with-stage-i-melanoma-compared-to-american-joint-committee-on-cancer-8th-edition-staging/2462252/Results from a recent study showed the potential of a 31-gene expression profile (31-GEP) test in improving the prognosis for patients diagnosed with stage I cutaneous melanoma. Despite being considered at low risk for metastasis or melanoma-specific death, patients with stage I cutaneous
- La Roche-Posay Launches New Dark Spot Serumhttps://practicaldermatology.com/news/la-roche-posay-launches-dark-spot-serum/2462254/La Roche-Posay, a subsidiary of L'oreal, recently announced the launch of its new a new serum corrector for dark spots, the Mela B3 Dark Spot Serum with MelasylTM + Nicinamide. According to the manufacturer, the launch was preceded by 18 years of research, as well as rese
- Fear of Cancer Recurrence Elevated Among Survivors of Localized Cutaneous Melanoma: Analysishttps://practicaldermatology.com/news/lived-experiences-and-fear-of-cancer-recurrence-among-survivors-of-localized-cutaneous-melanoma/2462249/Patients who suffer from localized cutaneous melanoma report high levels of fear of cancer recurrence, according to a new analysis. Researchers investigating the psychological well-being and fear of cancer recurrence among survivors of localized cutaneous melanoma in the United States ev
- Galderma Announces Filing Acceptance for Investigational Prurigo Nodularis and AD Treatmenthttps://practicaldermatology.com/news/galderma-announces-filing-recepetion-for-investigational-prurigo-nodularis-treatment/2462243/Galderma announced the acceptance of its Biologics License Applications for nemolizumab, a first-in-class monoclonal antibody IL-31 inhibitor, for the treatment of prurigo nodularis in adults and adolescents with moderate-to-severe atopic dermatitis (AD). The agency, according to a news
- Cutera Announces International Commercial Launch of AviClear for the Treatment of Acnehttps://practicaldermatology.com/news/cutera-announces-international-commercial-launch-of-aviclear-for-the-treatment-of-acne/2462240/Cutera announced the international limited commercial release of AviClear, which the company describes as the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. AviClear is now commercially available, on a limited basis, in the UK, Europe, a
- JAK-STAT Inhibitors Not Linked with Significant Increase in Cardiovascular Eventshttps://practicaldermatology.com/news/short-term-cardiovascular-complications-in-dermatology-patients-receiving-jak-stat-inhibitors/2462236/A new systematic review looking at the potential cardiovascular risks associated with Janus kinase–signal transducer and activator of transcription inhibitors (JAK-STATi) showed no safety signals in the short term. The findings bring a nuanced perspective on the safety profile of systemic
- American Academy of Dermatology Issues Updated Guidelines for the Management of Acnehttps://practicaldermatology.com/news/american-academy-of-dermatology-issues-updated-guidelines-for-the-management-of-acne/2462235/Acne is the most common skin condition in the United States, affecting nearly 50 million Americans each year, with symptoms usually beginning in puberty. Acne affects 85% of adolescents and can also often begin or continue in adulthood, especially in women. To help ensure that
- Highlights from Maui Derm 2024https://practicaldermatology.com/news/highlights-from-maui-derm-2024/2462227/The Maui Derm 2024 Conference showcased a wide array of advancements in dermatology, from innovative treatments to exciting new therapies, to business opportunities to the latest research. Here, Practical Dermatology recap
- Deucravacitinib Shows Sustained Response, Safety Profile: Analyseshttps://practicaldermatology.com/news/deucravacitinib-shows-sustained-response-safety-profile-analyses/2462221/Deucravacitinib (SOTYKTU, Bristol Myers Squibb) is a first-in-class, oral, selective allosteric TYK2 inhibitor, and has been approved in the United States, European Union, and other countries for use in adults with mode